弗斯特羅定
|
|
|
- CAS號:
- 286930-02-7
- 英文名:
- (R) Fesoterodine
- 英文別名:
- Fexodine;PF-00695838;Fesoterodine;Unii-621G617227;(R) Fesoterodine;2-Methylpropionic acid 2-[3-(N,N-diisopropylamino)-1(R)-phen...;(R)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl isobutyrate;2-Methylpropanoic acid 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester;Propanoic Acid 2-Methyl- 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl Ester;Desfesoterodine,Fesoterodine,OAB,muscarinic,overactive,Inhibitor,SPM7605,mAChR,orally,5-HMT,antimuscarinic,bladder,Muscarinic acetylcholine receptor,inhibit,receptor
- 中文名:
- 弗斯特羅定
- 中文別名:
- 弗斯特羅定;富馬酸弗斯特羅定雜質(zhì);化合物：Fesoterodine CAS:286930-02-7;化合物:Fesoterodine CAS:286930-02-7
- CBNumber:
- CB61175365
- 分子式:
- C26H37NO3
- 分子量:
- 411.58
- MOL File:
- 286930-02-7.mol
|
|
|
弗斯特羅定化學(xué)性質(zhì)
-
密度:
-
1.043
-
|
-
儲存條件:
-
Store at -20°C,unstable in solution, ready to use.
-
|
-
溶解度:
-
Ethanol: 100 mg/mL (242.97 mM)
-
|
-
形態(tài):
-
Viscous Liquid
-
|
-
顏色:
-
Colorless to light yellow
-
|
弗斯特羅定性質(zhì)、用途與生產(chǎn)工藝
弗斯特羅定(fesoterodine，商品名ToviazTM)是一種新型M受體阻滯劑，在體內(nèi)迅速代謝成活性代謝產(chǎn)物而發(fā)揮作用。
弗斯特羅定于2008年10月31日獲得美國FDA批準(zhǔn)上市，用于治療膀胱過度活動癥(overactivebladder，OAB)。
Fesoterodine 是一種口服有效，非亞型選擇性的，競爭性毒蕈堿受體 (mAChR) 拮抗劑，對 M1，M2，M3，M4，M5 受體的 pKi 值分別為 8.0，7.7，7.4，7.3，7.5。Fesoterodine 用于膀胱過度活動癥 (OAB)。
pKi: 8.0 (M1), 7.7 (M2), 7.4 (M3), 7.3 (M4) and 7.5 (M5)
Fesoterodine decreases micturition frequency, urgency severity and urgency incontinence episodes and increases the volume voided with each micturition.
After oral administration, Fesoterodine is rapidly and extensively hydrolysed in plasma by nonspecific esterases to Desfesoterodine (5-hydroxymethyl tolterodine; SPM 7605; HY-76569; an active metabolite of Fesoterodine).
Fesoterodine (0.01-1 mg/kg; IV) reduces the micturition pressure and increases bladder capacity and ICIs (intercontraction intervas) at the lowest dose tested of 0.01 mg/kg.
|
Animal Model:
|
Bladders from female Sprague-Dawley rats (225-275 g)
|
|
Dosage:
|
0.01, 0.1 and 1 mg/kg
|
|
Administration:
|
IV
|
|
Result:
|
Reduced the micturition pressure and increased bladder capacity and ICIs at the lowest dose tested of 0.01 mg/kg.
|
弗斯特羅定
上下游產(chǎn)品信息
上游原料
下游產(chǎn)品
| 更新日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS編號 | 包裝 | 價格 |
|---|
| 2026/06/05 | HY-70053 | 弗斯特羅定
Fesoterodine | 286930-02-7 | 1 mg | 273元 |
| 2026/06/05 | HY-70053 | 弗斯特羅定
Fesoterodine | 286930-02-7 | 5 mg | 600元 |
286930-02-7, 弗斯特羅定 相關(guān)搜索:
- 抑制劑
- 266930-03-8
- 化合物：Fesoterodine CAS:286930-02-7
- 化合物:Fesoterodine CAS:286930-02-7
- 富馬酸弗斯特羅定雜質(zhì)
- 弗斯特羅定
- 286930-02-7
- Fexodine
- Desfesoterodine,Fesoterodine,OAB,muscarinic,overactive,Inhibitor,SPM7605,mAChR,orally,5-HMT,antimuscarinic,bladder,Muscarinic acetylcholine receptor,inhibit,receptor
- 2-Methylpropionic acid 2-[3-(N,N-diisopropylamino)-1(R)-phen...
- PF-00695838
- (R)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl isobutyrate
- Unii-621G617227
- Fesoterodine
- 2-Methylpropanoic acid 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester
- Propanoic Acid 2-Methyl- 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl Ester
- (R) Fesoterodine